Constellation Pharmaceuticals rehires Jigar Raythatha as CEO

Private biotech firm Constellation Pharmaceuticals has appointed Jigar Raythatha as president and chief executive officer.

He is rejoining Constellation from Jounce Therapeutics, where he led business strategy and development since December 2012.

Mr Raythatha was previously head of corporate development at Constellation, where he led business development, strategy, and program management functions.

“I am pleased to return to Constellation at a time when the company is poised for breakout success,” said Mr Raythatha.

“The team has done a fantastic job driving multiple clinical programs through Phase I, and I look forward to working with everyone here to build on this progress and translate the company’s stellar science into meaningful outcomes for cancer patients.”

Earlier in his career, Mr Raythatha held roles of increasing responsibility at Biogen (Nasdaq: BIIB), Red Abbey Venture Partners, and AT. Kearney. He earned a Master of Business Administration from Columbia University and a Bachelor of Arts in biochemistry and economics from Rutgers University.

The company is also appointing James Audia, who has served as chief scientific officer of the company since 2011, as an independent member of the board of directors and a special scientific advisor to the company.